Importantly, in vivo administration of cysteamine strongly reduced tumor size (Figs 3C and S4A) with partial (Glut1, Pdk1, and Hk2) modification of their hypoxic transcriptional signature (Fig S4B) but without affecting their differentiation status (Fig S4C). This evidence concerns the gene SLC2A1 and neoplasm.